Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Randomized, Saline-Controlled, Single-Blind, Multiple Ascending Dose, Dose-Escalation, Multi-Center Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Trial Profile

A Phase 1/2 Randomized, Saline-Controlled, Single-Blind, Multiple Ascending Dose, Dose-Escalation, Multi-Center Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Mar 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PTR 01 (Primary)
  • Indications Epidermolysis bullosa dystrophica
  • Focus Adverse reactions; First in man
  • Sponsors Phoenix Tissue Repair

Most Recent Events

  • 08 Mar 2021 Status changed from active, no longer recruiting to completed.
  • 10 Jul 2020 According to a Phoenix Tissue Repair media release, interim data from this trial will be presented at Society for Pediatric Dermatologys (SPD) 45th Annual Meeting, to be held virtually July 10 to 12, 2020.
  • 30 Jun 2020 Planned primary completion date changed from 31 Jul 2020 to 30 Nov 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top